Department of Obstetrics and Gynecology, Handan Central Hospital, Handan, China.
J Clin Lab Anal. 2021 Aug;35(8):e23793. doi: 10.1002/jcla.23793. Epub 2021 Jul 1.
Chaperonin-containing tailless complex polypeptide subunit 6A (CCT6A) is a critical regulator and newly identified clinical biomarker of several cancers, while its correlation with the clinical characteristics and prognosis of cervical cancer patients is unclear. Therefore, this study aimed to explore this issue.
Chaperonin-containing tailless complex polypeptide subunit 6A expression in tumor and tumor-adjacent tissues from 198 cervical cancer patients who underwent resection were detected by immunohistochemistry assay and reverse transcription-quantitative polymerase chain reaction. Besides, the clinicopathological features and survival data of cervical cancer patients were collected.
Chaperonin-containing tailless complex polypeptide subunit 6A protein and mRNA levels were both increased in tumor tissues compared with tumor-adjacent tissues (both p < 0.001). Receiver operating characteristic curves showed that CCT6A protein (AUC: 0.774, 95% CI: 0.729-0.819) and mRNA levels (AUC: 0.904, 95% CI: 0.874-0.934) well discriminated tumor tissues from tumor-adjacent tissues. Besides, correlation analyses found that CCT6A protein and mRNA levels were positively correlated with lymph node metastasis and FIGO stage (all p < 0.05), apart from which CCT6A mRNA level was also positively associated with tumor size (p = 0.032). In addition, CCT6A protein and mRNA levels were negatively correlated with accumulating disease-free survival (both p < 0.05); meanwhile CCT6A mRNA level was negatively associated with accumulating overall survival as well (p = 0.010).
Chaperonin-containing tailless complex polypeptide subunit 6A is elevated in tumor tissues, and its high expression associates with larger tumor size, lymph node metastasis, higher FIGO stage, and worse prognosis in cervical cancer patients.
伴侣蛋白含尾复合物多肽亚基 6A（CCT6A）是几种癌症的关键调节因子和新鉴定的临床生物标志物，但其与宫颈癌患者临床特征和预后的相关性尚不清楚。因此，本研究旨在探讨这一问题。
采用免疫组织化学法和逆转录定量聚合酶链反应检测 198 例宫颈癌患者切除肿瘤及肿瘤旁组织中 CCT6A 的表达，并收集宫颈癌患者的临床病理特征和生存数据。
肿瘤组织中 CCT6A 蛋白和 mRNA 水平均高于肿瘤旁组织（均 P<0.001）。受试者工作特征曲线显示，CCT6A 蛋白（AUC：0.774，95%CI：0.729-0.819）和 mRNA 水平（AUC：0.904，95%CI：0.874-0.934）均能较好地区分肿瘤组织和肿瘤旁组织。此外，相关性分析发现，CCT6A 蛋白和 mRNA 水平与淋巴结转移和 FIGO 分期均呈正相关（均 P<0.05），CCT6A mRNA 水平还与肿瘤大小呈正相关（P=0.032）。此外，CCT6A 蛋白和 mRNA 水平与无病生存累积呈负相关（均 P<0.05）；同时，CCT6A mRNA 水平与总生存累积也呈负相关（P=0.010）。
CCT6A 在肿瘤组织中表达升高，其高表达与宫颈癌患者肿瘤较大、淋巴结转移、FIGO 分期较高和预后较差相关。
